| 1 |
29468456 | Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors. | 2018 Apr |
1 |
| 2 |
28120036 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). | 2017 Feb |
1 |
| 3 |
29181069 | Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. | 2017 Oct |
1 |
| 4 |
25332069 | Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. | 2016 Mar |
1 |
| 5 |
27765348 | Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients. | 2016 Nov 15 |
1 |
| 6 |
24346857 | Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. | 2015 Feb |
2 |
| 7 |
25043125 | Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft. | 2015 Sep |
4 |
| 8 |
26020033 | Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. | 2015 Mar |
2 |
| 9 |
26097873 | Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. | 2015 |
1 |
| 10 |
24309512 | Multi-kinase inhibition in ovarian cancer. | 2014 Jan |
1 |
| 11 |
24399106 | Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. | 2014 Jun |
1 |
| 12 |
24786603 | Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. | 2014 May 27 |
1 |
| 13 |
25173458 | TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. | 2014 Nov |
1 |
| 14 |
26158148 | Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. | 2014 Jun |
1 |
| 15 |
23263993 | A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. | 2013 Aug |
2 |
| 16 |
23591401 | A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. | 2013 Jul |
1 |
| 17 |
23811306 | Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. | 2013 Nov |
1 |
| 18 |
23876062 | A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. | 2013 Jul 22 |
2 |
| 19 |
22678005 | Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases. | 2012 Mar-Apr |
1 |
| 20 |
22767146 | Sorafenib in advanced melanoma: a critical role for pharmacokinetics? | 2012 Jul 24 |
1 |
| 21 |
23277740 | Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study. | 2012 |
1 |
| 22 |
20521052 | A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. | 2011 Apr |
1 |
| 23 |
20593250 | Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. | 2011 Dec |
1 |
| 24 |
20706860 | Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. | 2011 Dec |
2 |
| 25 |
21224376 | Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. | 2011 Mar 1 |
1 |
| 26 |
21240686 | Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. | 2011 Jan |
1 |
| 27 |
21954442 | Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. | 2011 Dec |
4 |
| 28 |
21036880 | Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. | 2010 |
4 |
| 29 |
21122388 | [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]. | 2010 Sep |
1 |
| 30 |
21122420 | [Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma]. | 2010 Aug |
1 |
| 31 |
19101137 | Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. | 2009 Mar |
1 |
| 32 |
18477034 | Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. | 2008 Jul |
2 |
| 33 |
18765530 | Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. | 2008 Sep 1 |
1 |